|
|
|
|
Science fiction? Aerosol delivery of an engineered virus halts lung cancer progression in mice
Nasal sprays containing special viruses may revolutionize the field of pharmacology to correct a multitude of devastating genetic and sporadic human diseases including lung cancer.Lung cancer in conjunction with liver and...
|
|
|
PET-CT improves preoperative staging of non-small cell lung cancer
NEW YORK (Reuters Health) - Combined positron-emission tomography and computed tomography (PET-CT) improves the staging of non-small cell lung cancer (NSCLC) and also reduces the numbers of total and futile...
|
|
|
Recognition of subtype non-small cell lung cancer by DNA aptamers selected from living cells
Zilong Zhao, Li Xu, Xiaoli Shi, Weihong Tan, Xiaohong Fang and Dihua Shangguan In this work, we have developed new aptamer probes for non-small cell lung cancer (NSCLC) by directing the aptamer selection process...
|
|
|
OncQuest Labs launches K-RAS Mutation Analysis for diagnosis of colorectal & lung cancers
OncQuest Laboratories Ltd., a pioneer in Indian oncology clinical testing, has introduced the K-RAS Mutation Analysis for determining therapeutic response of the targeted therapies in colorectal and lung cancers.The technologically...
|
|
|
PET-CT improves preoperative staging of non-small cell lung cancer
NEW YORK (Reuters Health) - Combined positron-emission tomography and computed tomography (PET-CT) improves the staging of non-small cell lung cancer (NSCLC) and also reduces the numbers of total and futile...
|
|
|
Gefitinib Receives European Licence For The Treatment Of Lung Cancer For Patients With EGFR Activating Mutatio
AstraZeneca announced that it has received a licence by the European Medicines Agency (EMEA) for its oral targeted anti-cancer drug, gefitinib, for EGFR (epidermal growth factor receptor-tyrosine kinase) activating mutation positive patients...
|
|
|
AstraZeneca get European go-ahead for lung cancer drug
Tagged: AstraZeneca Business Cancer Disease European Union Health Health care Lung cancer Medicine Pharmaceutical industry Pharmaceuticals IRESSA (Gefitinib) receives marketing authorization for the treatment of non-small ...
|
|
|
How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question
The spiraling cost of cancer care, in particular the cost of cancer therapeutics that achieve only marginal benefits, is under increasing scrutiny.Although health-care professionals avoid putting a value on a life, our limited resources...
|
|
|
AstraZeneca gets green light for gefitinib and prepares to submit fixed payment scheme to NICE
Patients with non-small cell lung cancer will have oral treatment soon (Doctorkan/dreamstime.com) AstraZenecas anticancer drug gefitinib (Iressa) has been given the green light from the European Agency, making it the...
|
|
|
PET-CT scanners reduce futile lung cancer surgery
BOSTON (Reuters) - Devices that simultaneously take a PET scan and a CT scan can eliminate unnecessary surgery for lung cancer, although they do little to save lives, researchers in Denmark reported on Wednesday.'Our study is the...
|
|
|
Pfizer Discontinues Phase 3 Trial of Sutent in Metastatic Colorectal Cancer
We are disappointed with this result, but trial successes and failures are an integral part of cancer drug development and contribute to a growing body of knowledge on improving patient care, said Dr.Mace Rothenberg, senior vice president...
|
|
|
Iressa (Gefitinib) Receives Marketing Authorisation for the Treatment of Non-Small Cell Lung Cancer in Europe
-AstraZeneca announced today that the European Commission has granted marketing authorisation for the oral anti-cancer drug, IRESSA for the treatment of adults with locally advanced or metastatic non-small cell lung...
|
|
|
::: IRESSA (Gefitinib) Receives Marketing Authorisation for the Treatment of Non-Small Cell Lung Cancer in Eur
AstraZeneca announced today that the European Commission has granted marketing authorisation for the oral anti-cancer drug, IRESSA for the treatment of adults with locally advanced or metastatic non-small cell lung...
|
|
|
IRESSA (Gefitinib) Receives Marketing Authorisation for the Treatment of Non-Small Cell Lung Cancer in Europe
3652 live jobs on PharmiWeb.com now AstraZeneca announced today that the European Commission has granted marketing authorisation for the oral anti-cancer drug, IRESSA for the treatment of adults with locally advanced or metastatic non-...
|
|
|
AstraZeneca's Lung Cancer Drug Iressa Gets Approval In Europe - Update
AM ET RELATED NEWS TOP MARKET NEWS (RTTNews) - Wednesday, Anglo-Swedish drug giant AstraZeneca plc (AZN: News )(AZN.L: News ) announced that its oral anti-cancer drug Iressa has been granted marketing authorisation for the treatment of ...
|
|
|
Iressa (Gefitinib) Receives Marketing Authorisation for the Treatment of Non-Small Cell Lung Cancer in Europe
-AstraZeneca announced today that the European Commission has granted marketing authorisation for the oral anti-cancer drug, IRESSA for the treatment of adults with locally advanced or metastatic non-small cell lung...
|
|
|
Iressa (Gefitinib) Receives Marketing Authorisation for the Treatment of Non-Small Cell Lung Cancer in Europe
- IRESSA acts by inhibiting the tyrosine kinase enzyme in the EGFR, thus blocking the transmission of signals involved in the growth and spread of tumours.A mutation in the EGFR is a characteristic occurring in 10-15% of lung...
|
|
|
AstraZeneca's IRESSA Gets Marketing Authorisation For Treatment Of Non-small Cell Lung Cancer In Europe - Quic
AM ET RELATED NEWS TOP MARKET NEWS (RTTNews) - AstraZeneca Plc (AZN: News ,AZN.L: News ) announced that the European Commission has granted marketing authorisation for the oral anti-cancer drug, IRESSA for the treatment of adults with...
|
|
|
AstraZeneca's Iressa gets E.U. marketing approval
LONDON (Menafn - MarketWatch) -- Anglo-Swedish drugmaker AstraZeneca said Wednesday that one of its previously-sidelined drugs has obtained European marketing authorization, a move that could inject more life into the firm's drug portfolio....
|
|
|
Boehringer Ingelheim and DxS in lung cancer diagnostic deal
INGELHEIM, Germany-Boehringer Ingelheim and DxS have partnered on a clinical trial to identify likely responders to new treatment for non-small cell lung cancer, the companies announced in June.Financial terms of...
|
|
|
Europe approves AstraZeneca lung cancer drug
AstraZeneca's once-daily cancer pill Iressa has been approved for certain lung cancer patients in Europe, reviving the fortunes of a product that had until recently been largely written off by industry analysts.The drugmaker said on...
|
|
|
UPDATE 1-Europe approves AstraZeneca lung cancer drug
LONDON, July 1 (Reuters) - AstraZeneca's once-daily cancer pill Iressa has been approved for certain lung cancer patients in Europe, reviving the fortunes of a product that had until recently been largely written off by industry...
|
|
|
UPDATE 1-Europe approves AstraZeneca lung cancer drug
LONDON, July 1 (Reuters) - AstraZeneca's once-daily cancer pill Iressa has been approved for certain lung cancer patients in Europe, reviving the fortunes of a product that had until recently been largely written off by industry...
|
|
|
UPDATE 1-Europe approves AstraZeneca lung cancer drug
LONDON, July 1 (Reuters) - AstraZeneca's once-daily cancer pill Iressa has been approved for certain lung cancer patients in Europe, reviving the fortunes of a product that had until recently been largely written off by industry...
|
|
|
HRT ups death risk for women with lung cancer
Women's Health News Health Encyclopedia: Women's Health SATURDAY, May 30 (HealthDay News) -- The current use of combined hormone replacement therapy (HRT) is associated with a higher risk of dying for women diagnosed with non-small...
|
